Xilio Therapeutics, Inc.
XLO Nasdaq Pharmaceutical Preparations Financials FY2020–FY2025
Revenue
Total sales reported in the income statement.
$43.8M
589.9%
vs prior year
Operating margin
Operating income as a share of revenue.
−95.9%
859.0 pts
Net income
Profit after all expenses, interest and tax.
−$35.0M
Free cash flow
Cash from operations minus capital spending.
−$5.5M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On −$0.31 EPS (TTM)
What Xilio Therapeutics, Inc. does
No business description yet.
- Legal name
- Xilio Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Accession · CIK
- 0001193125-26-118550
0001840233
Revenue and margins
Xilio Therapeutics, Inc. had $43.8M of revenue in fiscal 2025, up 589.9% on the year before.
FY20
Revenue —
FY21
Revenue —
FY22
Revenue —
FY23
Revenue —
FY24
Revenue $6.3M
FY25
Revenue $43.8M
Q3 '23
Revenue —
Q4 '23
Revenue —
Q1 '24
Revenue —
Q2 '24
Revenue $2.4M
Q3 '24
Revenue $2.3M
Q4 '24
Revenue $1.7M
Q1 '25
Revenue $2.9M
Q2 '25
Revenue $8.1M
Q3 '25
Revenue $19.1M
Q4 '25
Revenue $13.7M
Q1 '26
Revenue $12.6M
Q2 '26
Revenue $18.7M
FY20
Gross —
Operating —
Net —
FCF —
FY21
Gross —
Operating —
Net —
FCF —
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating −954.9%
Net −918.0%
FCF −290.3%
FY25
Gross —
Operating −95.9%
Net −80.1%
FCF −12.6%
Gross
Operating
Net
FCF
Q3 '23
Gross —
Operating —
Net —
FCF —
Q4 '23
Gross —
Operating —
Net —
FCF —
Q1 '24
Gross —
Operating —
Net —
FCF —
Q2 '24
Gross —
Operating −623.8%
Net −590.8%
FCF —
Q3 '24
Gross —
Operating −652.3%
Net −619.5%
FCF −604.6%
Q4 '24
Gross —
Operating −790.5%
Net −759.5%
FCF −821.5%
Q1 '25
Gross —
Operating −472.7%
Net −452.7%
FCF 988.3%
Q2 '25
Gross —
Operating −177.7%
Net −196.0%
FCF −184.0%
Q3 '25
Gross —
Operating −10.1%
Net −85.4%
FCF −91.8%
Q4 '25
Gross —
Operating −86.5%
Net 75.7%
FCF −15.3%
Q1 '26
Gross —
Operating −111.6%
Net −75.3%
FCF −181.0%
Q2 '26
Gross —
Operating −18.7%
Net −34.1%
FCF −100.5%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income −$55.2M
FY21
Net income −$75.8M
FY22
Net income −$88.2M
FY23
Net income −$76.4M
FY24
Net income −$58.2M
FY25
Net income −$35.0M
Q3 '23
Net income −$16.7M
Q4 '23
Net income −$17.7M
Q1 '24
Net income −$17.2M
Q2 '24
Net income −$13.9M
Q3 '24
Net income −$14.0M
Q4 '24
Net income −$13.1M
Q1 '25
Net income −$13.3M
Q2 '25
Net income −$15.8M
Q3 '25
Net income −$16.3M
Q4 '25
Net income $10.4M
Q1 '26
Net income −$9.5M
Q2 '26
Net income −$6.4M
FY20
Diluted EPS −$105.42
FY21
Diluted EPS −$13.52
FY22
Diluted EPS −$3.22
FY23
Diluted EPS −$2.78
FY24
Diluted EPS −$15.24
FY25
Diluted EPS −$4.19
Q3 '23
Diluted EPS −$0.61
Q4 '23
Diluted EPS −$0.64
Q1 '24
Diluted EPS −$0.62
Q2 '24
Diluted EPS −$0.24
Q3 '24
Diluted EPS −$0.22
Q4 '24
Diluted EPS −$14.16
Q1 '25
Diluted EPS −$2.49
Q2 '25
Diluted EPS −$2.30
Q3 '25
Diluted EPS −$0.11
Q4 '25
Diluted EPS $0.71
Q1 '26
Diluted EPS −$0.58
Q2 '26
Diluted EPS −$0.33
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital —
Return on equity —
Return on assets −152.0%
FY21
Return on capital —
Return on equity −148.4%
Return on assets −59.6%
FY22
Return on capital —
Return on equity −60.6%
Return on assets −49.4%
FY23
Return on capital —
Return on equity −107.3%
Return on assets −76.4%
FY24
Return on capital —
Return on equity −214.0%
Return on assets −88.2%
FY25
Return on capital —
Return on equity −132.5%
Return on assets −31.0%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$5.5M in fiscal 2025, −12.6% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow −$38.3M
FY21
Free cash flow −$81.9M
FY22
Free cash flow −$77.6M
FY23
Free cash flow −$69.1M
FY24
Free cash flow −$18.4M
FY25
Free cash flow −$5.5M
Q3 '23
Free cash flow −$13.4M
Q4 '23
Free cash flow −$13.4M
Q1 '24
Free cash flow —
Q2 '24
Free cash flow —
Q3 '24
Free cash flow −$13.7M
Q4 '24
Free cash flow −$14.2M
Q1 '25
Free cash flow $29.0M
Q2 '25
Free cash flow −$14.9M
Q3 '25
Free cash flow −$17.5M
Q4 '25
Free cash flow −$2.1M
Q1 '26
Free cash flow −$22.9M
Q2 '26
Free cash flow −$18.8M
FY20
Cash from operations −$36.1M
Capital spending $2.2M
FY21
Cash from operations −$80.8M
Capital spending $1.1M
FY22
Cash from operations −$75.7M
Capital spending $1.9M
FY23
Cash from operations −$68.6M
Capital spending $0.5M
FY24
Cash from operations −$18.4M
Capital spending $0.0M
FY25
Cash from operations −$5.0M
Capital spending $0.5M
Cash from operations
Capital spending
Q3 '23
Cash from operations −$13.4M
Capital spending $0.0M
Q4 '23
Cash from operations −$13.4M
Capital spending $0.0M
Q1 '24
Cash from operations −$10.5M
Capital spending —
Q2 '24
Cash from operations $20.0M
Capital spending —
Q3 '24
Cash from operations −$13.7M
Capital spending $0.0M
Q4 '24
Cash from operations −$14.2M
Capital spending $0.0M
Q1 '25
Cash from operations $29.0M
Capital spending $0.0M
Q2 '25
Cash from operations −$14.5M
Capital spending $0.4M
Q3 '25
Cash from operations −$17.5M
Capital spending $0.0M
Q4 '25
Cash from operations −$2.0M
Capital spending $0.1M
Q1 '26
Cash from operations −$22.3M
Capital spending $0.6M
Q2 '26
Cash from operations −$18.8M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
Xilio Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY20
Diluted shares —
FY21
Diluted shares —
FY22
Diluted shares —
FY23
Diluted shares —
FY24
Diluted shares —
FY25
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably Xilio Therapeutics, Inc. can carry it.
FY20
Cash $19.2M
Debt —
FY21
Cash $198M
Debt —
FY22
Cash $120M
Debt —
FY23
Cash $44.7M
Debt —
FY24
Cash $55.3M
Debt —
FY25
Cash $138M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $198M | $120M | $44.7M | $55.3M | $138M |
| Current ratio | 15.8x | 5.9x | 3.0x | 2.2x | 2.6x |
| Quick ratio | 15.8x | 5.9x | 3.0x | 2.2x | 2.6x |
| Total assets | $218M | $139M | $60.9M | $71.1M | $155M |
| Total liabilities | $32.6M | $33.5M | $24.1M | $53.5M | $119M |
| Shareholders' equity | $185M | $106M | $36.8M | $17.6M | $35.3M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ | ✕ | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — | — | — |
| Current ratio rose | — | ✓ | ✕ | ✕ | ✕ | ✓ |
| Share count didn't rise | — | — | — | — | — | — |
| Gross margin rose | — | — | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — | — | ✓ |
| F-score | — / 3 | — / 5 | — / 5 | — / 5 | — / 5 | — / 6 |
| Accruals ratio | −52.7% | 3.9% | −7.0% | −7.8% | −60.4% | −26.6% |
| Altman Z'' | −20.12 | 6.96 | −1.96 | −21.08 | −19.94 | −6.58 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | $6.3M | $43.8M |
| Research and development | $43.9M | $51.2M | $59.2M | $52.1M | $41.2M | $56.0M |
| Operating income | −$54.6M | −$75.0M | −$89.1M | −$79.1M | −$60.6M | −$42.0M |
| Pretax income | — | — | — | — | −$58.2M | −$35.0M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$55.2M | −$75.8M | −$88.2M | −$76.4M | −$58.2M | −$35.0M |
| Diluted EPS | −$105.42 | −$13.52 | −$3.22 | −$2.78 | −$15.24 | −$4.19 |
| Cash flow | ||||||
| Cash from operations | −$36.1M | −$80.8M | −$75.7M | −$68.6M | −$18.4M | −$5.0M |
| Capital expenditure | $2.2M | $1.1M | $1.9M | $0.5M | $0.0M | $0.5M |
| Free cash flow | −$38.3M | −$81.9M | −$77.6M | −$69.1M | −$18.4M | −$5.5M |
| Depreciation and amortization | $1.1M | $1.5M | $1.8M | $1.9M | $1.6M | $1.5M |
| Stock-based compensation | $1.3M | $5.0M | $8.4M | $7.4M | $6.4M | $6.9M |
| Balance sheet | ||||||
| Cash and short-term investments | $19.2M | $198M | $120M | $44.7M | $55.3M | $138M |
| Finance lease liabilities | — | $0.2M | $0.1M | $0.0M | — | — |
| Current assets | $20.6M | $203M | $124M | $48.1M | $60.2M | $145M |
| Current liabilities | $22.2M | $12.8M | $21.1M | $16.0M | $27.3M | $56.3M |
| Property and equipment, net | $7.4M | $7.6M | $7.3M | $5.9M | $4.5M | $3.9M |
| Total assets | $36.3M | $218M | $139M | $60.9M | $71.1M | $155M |
| Total liabilities | $41.6M | $32.6M | $33.5M | $24.1M | $53.5M | $119M |
| Shareholders' equity | −$83.3M | $185M | $106M | $36.8M | $17.6M | $35.3M |
| Margins | ||||||
| Operating margin | — | — | — | — | −954.9% | −95.9% |
| EBITDA margin | — | — | — | — | −929.0% | −92.4% |
| Net margin | — | — | — | — | −918.0% | −80.1% |
| FCF margin | — | — | — | — | −290.3% | −12.6% |
| Returns | ||||||
| Return on capital employed | −385.3% | −36.6% | −75.5% | −176.0% | −138.3% | −42.7% |
| Return on equity | — | −148.4% | −60.6% | −107.3% | −214.0% | −132.5% |
| Return on assets | −152.0% | −59.6% | −49.4% | −76.4% | −88.2% | −31.0% |
| Return on tangible equity | — | −40.9% | −83.5% | −207.5% | −331.0% | −99.3% |
| Growth | ||||||
| Revenue growth | — | — | — | — | — | 589.9% |
| Financial health | ||||||
| Current ratio | 0.9x | 15.8x | 5.9x | 3.0x | 2.2x | 2.6x |
| Quick ratio | 0.9x | 15.8x | 5.9x | 3.0x | 2.2x | 2.6x |
| Capital allocation | ||||||
| Capex / revenue | — | — | — | — | 0.6% | 1.2% |
| Stock comp / revenue | — | — | — | — | 101.4% | 15.9% |
| Quality scores | ||||||
| Altman Z'' | −20.1 | 7.0 | −2.0 | −21.1 | −19.9 | −6.6 |
| Accruals ratio | −52.7% | 3.9% | −7.0% | −7.8% | −60.4% | −26.6% |
Source: SEC EDGAR XBRL filings (CIK 0001840233). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.